Table 4 Survival of high-risk genetic... | American Society of Hematology

Table 4

Survival of high-risk genetic subgroups on randomized controlled clinical trials of untreated MM

Genetics	N1/N2	End point	Arm 1	Arm 2	Arm 1, %	Arm 2, %	Comment
t(4;14)	26/24	3-y OS	V-AD/ASCT/Thal	Bz-AD/ASCT/Bz	44	66	HOVON/GMMG⁷
	98/106	4-y OS	VA*-D	Bz*-D	32	63*	IFM-2005³⁹
	21/23	2-y OS	Thal*	Placebo*	67	87	TT2⁴²
	21/29	2-y OS	Thal*-TT2	Bz*-TT3	67	97*	TT2 vs TT3⁴²
del17p	21/16	3-y OS	V-AD/ASCT/Thal	Bz-AD/ASCT/Bz	17	69*	HOVON/GMMG⁷
	119/54	4-y OS	VA*-D	Bz*-D	36	50	IFM-2005³⁹
Nonhyperdiploid	92	3-y OS	Thal*-D-Bz	Mel*-P-Bz	53	72*	PETHEMA⁴
Unfavorable FISH	152/141	3-y OS	Thal*-D-Cyclo	VA*-D-Cyclo	58	56	MRC IX intensive⁵¹
	96/90	3-y OS	Thal*-D-Cyclo	Placebo*-P-Mel	34	26	MRC IX nonintensive⁹
	99/98	3-y OS	Thal* maintenance	Placebo* maintenance	45	69*	MRC IX maintenance⁵⁴

Genetics	N1/N2	End point	Arm 1	Arm 2	Arm 1, %	Arm 2, %	Comment
t(4;14)	26/24	3-y OS	V-AD/ASCT/Thal	Bz-AD/ASCT/Bz	44	66	HOVON/GMMG⁷
	98/106	4-y OS	VA*-D	Bz*-D	32	63*	IFM-2005³⁹
	21/23	2-y OS	Thal*	Placebo*	67	87	TT2⁴²
	21/29	2-y OS	Thal*-TT2	Bz*-TT3	67	97*	TT2 vs TT3⁴²
del17p	21/16	3-y OS	V-AD/ASCT/Thal	Bz-AD/ASCT/Bz	17	69*	HOVON/GMMG⁷
	119/54	4-y OS	VA*-D	Bz*-D	36	50	IFM-2005³⁹
Nonhyperdiploid	92	3-y OS	Thal*-D-Bz	Mel*-P-Bz	53	72*	PETHEMA⁴
Unfavorable FISH	152/141	3-y OS	Thal*-D-Cyclo	VA*-D-Cyclo	58	56	MRC IX intensive⁵¹
	96/90	3-y OS	Thal*-D-Cyclo	Placebo*-P-Mel	34	26	MRC IX nonintensive⁹
	99/98	3-y OS	Thal* maintenance	Placebo* maintenance	45	69*	MRC IX maintenance⁵⁴

V indicates vincristine; A, adriamycin; D, dexamethasone; ASCT, autologous stem cell transplantation; Thal, thalidomide; Bz, bortezomib; TT2, Total Therapy 2; TT3, Total Therapy 3; Mel, low-dose oral melphalan; P, prednisone; Cyclo, cyclophosphamide; and /, sequential therapies.

The drugs randomized in Arm 1 versus Arm 2 and the survival outcomes that are significantly superior.

View Large

This Feature Is Available To Subscribers Only